[go: up one dir, main page]

WO2005077105A3 - Réduction de la réplication de vih-1 par l'apobec 3g - Google Patents

Réduction de la réplication de vih-1 par l'apobec 3g Download PDF

Info

Publication number
WO2005077105A3
WO2005077105A3 PCT/US2005/004483 US2005004483W WO2005077105A3 WO 2005077105 A3 WO2005077105 A3 WO 2005077105A3 US 2005004483 W US2005004483 W US 2005004483W WO 2005077105 A3 WO2005077105 A3 WO 2005077105A3
Authority
WO
WIPO (PCT)
Prior art keywords
hiv
apobec3g
replication
reduction
editing enzyme
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2005/004483
Other languages
English (en)
Other versions
WO2005077105A2 (fr
Inventor
Vinay K Pathak
Hongzhan Xu
Evguenia S Svarovskaia
Rebekah Barr
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
US Department of Health and Human Services
Original Assignee
US Department of Health and Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by US Department of Health and Human Services filed Critical US Department of Health and Human Services
Publication of WO2005077105A2 publication Critical patent/WO2005077105A2/fr
Anticipated expiration legal-status Critical
Publication of WO2005077105A3 publication Critical patent/WO2005077105A3/fr
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/775—Apolipopeptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • General Physics & Mathematics (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La présente invention a trait à des séquences d'APOBEC3G mutant de réduction de l'infection du VIH-1 en présence de VIH-Vif. Dans des modes de réalisation particuliers, les molécules d'APOBEC3G mutant comprennent (ou codent pour) une substitution D128A, D128E, D128K, ou D128V. L'invention a également trait à des procédés d'utilisation des molécules de l'invention pour la réduction de l'infection du VIH-1, par exemple pour le traitement d'un sujet atteint d'une infection du VIH-1.
PCT/US2005/004483 2004-02-11 2005-02-09 Réduction de la réplication de vih-1 par l'apobec 3g Ceased WO2005077105A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US54394104P 2004-02-11 2004-02-11
US60/543,941 2004-02-11

Publications (2)

Publication Number Publication Date
WO2005077105A2 WO2005077105A2 (fr) 2005-08-25
WO2005077105A3 true WO2005077105A3 (fr) 2006-09-21

Family

ID=34860481

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/US2005/004483 Ceased WO2005077105A2 (fr) 2004-02-11 2005-02-09 Réduction de la réplication de vih-1 par l'apobec 3g
PCT/US2005/004371 Ceased WO2005077099A2 (fr) 2004-02-11 2005-02-11 Reduction de la replication du vih-1 a l'aide de proteines mutantes apogec3g

Family Applications After (1)

Application Number Title Priority Date Filing Date
PCT/US2005/004371 Ceased WO2005077099A2 (fr) 2004-02-11 2005-02-11 Reduction de la replication du vih-1 a l'aide de proteines mutantes apogec3g

Country Status (1)

Country Link
WO (2) WO2005077105A2 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100365119C (zh) * 2005-10-21 2008-01-30 中国科学院生物物理研究所 抗hiv病毒的多肽及其编码基因与应用
US9243243B2 (en) 2006-08-31 2016-01-26 Nexigen Gmbh Means and methods for detecting protein-peptide interactions
JP2011115151A (ja) * 2009-11-05 2011-06-16 National Institute Of Advanced Industrial Science & Technology Ａｐｏｂｅｃ３ｇの活性測定方法
WO2019222537A1 (fr) * 2018-05-18 2019-11-21 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Variants catalytiquement hyperactifs de la protéine apobec3 humaine

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040009951A1 (en) * 2002-06-13 2004-01-15 Malim Michael H DNA deamination mediates innate immunity to (retro)viral infection
EP1629003B1 (fr) * 2003-05-23 2008-03-12 Oregon Health & Science University Procedes permettant d'identifier des inhibiteurs

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
KAO S. ET AL.: "The human Immunodeficiency Virus Type 1 Vif Protein Reduces Intracellular Expression and Inhibits Packaging of APOBEC3G (CEM15), a Cellular Inhibitor of Virus Infectivity", J. VIROL., vol. 77, November 2003 (2003-11-01), pages 11398 - 11407, XP002328602 *
MARIANI R. ET AL.: "Species-Specific Exclusion of APOBEC2G from HIV-1 Virions by Vif", CELL, vol. 114, July 2003 (2003-07-01), pages 21 - 31, XP002344957 *
SAWYER S. ET AL.: "Ancient Adaptive Evolution of the Primate Antiviral DNA-Editing Enzyme APOBEC3G", PLOS BIOL., vol. 2, September 2004 (2004-09-01), pages 1278 - 1285 *
SHEEHY A. ET AL.: "Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein", NATURE, vol. 418, August 2002 (2002-08-01), pages 646 - 650, XP002328600 *
ZHANG J. ET AL.: "Rapid evolution of primate antiviral enzyme APOBEC3G", HUM. MOL. GENET., vol. 13, June 2004 (2004-06-01), pages 1785 - 1791 *

Also Published As

Publication number Publication date
WO2005077099A2 (fr) 2005-08-25
WO2005077099A3 (fr) 2009-05-28
WO2005077105A2 (fr) 2005-08-25

Similar Documents

Publication Publication Date Title
WO2003088923A3 (fr) Procedes relatifs au traitement de l'occlusion intestinale
ZA200810113B (en) Method for the treatment and prevention of ocular disorders
UA85559C2 (en) Aminobenzophenone compounds
WO2003096983A3 (fr) Methode de traitement de troubles dyslipidemiques
TNSN05254A1 (en) Derivatives of 2-acylamino-4-phenylthiazole, preparation method thereof and application of same in therapeutics
IL195256A0 (en) Compositions of r(+)and s(-)pramipexole and methods of using the same
UA92355C2 (en) urn:schemas-microsoft-com:office:smarttags2,4-DIAMINO-PYRIMIDINES USED AS AURORAINHIBITORS
AU2003225800A1 (en) Azolylaminoazine as inhibitors of protein kinases
AU2003220299A1 (en) Azinylaminoazoles as inhibitors of protein kinases
AU2003218215A1 (en) Azolylaminoazines as inhibitors of protein kinases
WO2006004833A3 (fr) Inhibiteurs de kinase a base de pyrrolotriazine
EP1623046A4 (fr) Compositions et procedes pour traiter le syndrome respiratoire aigu severe
TW200633980A (en) Pyridones useful as inhibitors of kinases
WO2001087328A3 (fr) Inhibiteurs d"interleukine 1 dans le traitement de maladies
WO2005013892A3 (fr) Agents therapeutiques contenant du bore et a resistance hydrolytique et procedes pour les utiliser
HRP20041071A2 (en) Methods of treating hepatitis
WO2006034154A3 (fr) Sels de 5-azacytidine
WO2005118511A3 (fr) Composes, compositions et methodes permettant de stabiliser la transthyretine et d'inhiber un mauvais repliement de la transthyretine
WO2005018535A3 (fr) Compositions et procedes pour le traitement du syndrome respiratoire aigu severe (sras)
WO2005074598A3 (fr) Composes precurseurs de nitroxyle et methodes d'utilisation
TW200633992A (en) Biaryloxymethylarenecarboxylic acids
WO2005077099A3 (fr) Reduction de la replication du vih-1 a l'aide de proteines mutantes apogec3g
WO2004098599A3 (fr) Agents pour le traitement de troubles du bas-ventre
WO2003094967A3 (fr) Nouvelle combinaison destinee au traitement des troubles des voies aeriennes
EP1597234A4 (fr) Nouveaux composes

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase